nagilactone c has been researched along with Lung Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Feng, ZL; Jiang, XM; Li, A; Lin, LG; Lu, JJ; Su, MX; Wang, Y; Zhang, LL | 1 |
| Chen, X; Feng, ZL; Huang, MY; Jiang, XM; Li, A; Li, H; Lin, LG; Lu, JJ; Wang, Y; Zhang, LL | 1 |
2 other study(ies) available for nagilactone c and Lung Neoplasms
| Article | Year |
|---|---|
Downregulation of Cyclin B1 mediates nagilactone E-induced G2 phase cell cycle arrest in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclin B1; Diterpenes; Down-Regulation; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms | 2018 |
Nagilactone E suppresses TGF-β1-induced epithelial-mesenchymal transition, migration and invasion in non-small cell lung cancer cells.
Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Cell Movement; Diterpenes; Epithelial-Mesenchymal Transition; Ferns; Humans; Lung Neoplasms; Neoplasm Invasiveness; Seeds; Signal Transduction; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta1 | 2019 |